Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1946 1
1947 5
1948 9
1949 7
1950 9
1951 15
1952 19
1953 7
1954 17
1955 14
1956 5
1957 11
1958 8
1959 16
1960 15
1961 17
1962 11
1963 16
1964 27
1965 31
1966 24
1967 19
1968 26
1969 29
1970 27
1971 22
1972 26
1973 27
1974 18
1975 35
1976 49
1977 48
1978 55
1979 62
1980 61
1981 54
1982 67
1983 90
1984 93
1985 79
1986 82
1987 68
1988 87
1989 140
1990 126
1991 123
1992 147
1993 125
1994 132
1995 137
1996 138
1997 185
1998 194
1999 231
2000 234
2001 309
2002 339
2003 369
2004 383
2005 493
2006 438
2007 475
2008 528
2009 466
2010 534
2011 590
2012 619
2013 598
2014 685
2015 743
2016 775
2017 865
2018 1019
2019 1209
2020 1342
2021 1594
2022 1677
2023 1859
2024 760

Text availability

Article attribute

Article type

Publication date

Search Results

19,720 results

Results by year

Filters applied: . Clear all
Page 1
Atopic Dermatitis: Diagnosis and Treatment.
Frazier W, Bhardwaj N. Frazier W, et al. Am Fam Physician. 2020 May 15;101(10):590-598. Am Fam Physician. 2020. PMID: 32412211 Free article. Review.
Ultraviolet phototherapy is a safe and effective treatment for moderate to severe atopic dermatitis when first-line treatments are not adequate. ...Evidence is lacking to support the use of integrative medicine in the treatment of atopic …
Ultraviolet phototherapy is a safe and effective treatment for moderate to severe atopic dermatitis when first-line …
JAK inhibitors in the treatment of atopic dermatitis.
Chovatiya R, Paller AS. Chovatiya R, et al. J Allergy Clin Immunol. 2021 Oct;148(4):927-940. doi: 10.1016/j.jaci.2021.08.009. Epub 2021 Aug 24. J Allergy Clin Immunol. 2021. PMID: 34437922 Free PMC article. Review.
Atopic dermatitis (AD) is a chronic inflammatory skin disorder associated with heterogenous presentation and often immense patient burden. ...JAK inhibitors hold great promise as the next generation of targeted AD therapy. While their outstanding efficacy is …
Atopic dermatitis (AD) is a chronic inflammatory skin disorder associated with heterogenous presentation and often immense pat …
Innovation in the treatment of atopic dermatitis: Emerging topical and oral Janus kinase inhibitors.
Nakashima C, Yanagihara S, Otsuka A. Nakashima C, et al. Allergol Int. 2022 Jan;71(1):40-46. doi: 10.1016/j.alit.2021.10.004. Epub 2021 Nov 21. Allergol Int. 2022. PMID: 34815171 Free article. Review.
Atopic dermatitis (AD) is characterized by chronic, eczematous, severe pruritic skin lesions. ...Therefore, the emergence of these topical and oral JAK inhibitors would be regarded as an innovation in the treatment of atopic dermatitis....
Atopic dermatitis (AD) is characterized by chronic, eczematous, severe pruritic skin lesions. ...Therefore, the emergence of t …
The translational revolution in atopic dermatitis: the paradigm shift from pathogenesis to treatment.
Facheris P, Jeffery J, Del Duca E, Guttman-Yassky E. Facheris P, et al. Cell Mol Immunol. 2023 May;20(5):448-474. doi: 10.1038/s41423-023-00992-4. Epub 2023 Mar 16. Cell Mol Immunol. 2023. PMID: 36928371 Free PMC article. Review.
Atopic dermatitis (AD) is the most common inflammatory skin disease, and it is considered a complex and heterogeneous condition. ...In this review, we discuss the changes in the concepts of both the pathogenesis of and treatment approach to AD, highlight the …
Atopic dermatitis (AD) is the most common inflammatory skin disease, and it is considered a complex and heterogeneous conditio …
Novel insights into atopic dermatitis.
Schuler CF 4th, Billi AC, Maverakis E, Tsoi LC, Gudjonsson JE. Schuler CF 4th, et al. J Allergy Clin Immunol. 2023 May;151(5):1145-1154. doi: 10.1016/j.jaci.2022.10.023. Epub 2022 Nov 22. J Allergy Clin Immunol. 2023. PMID: 36428114 Review.
Recent research into the pathophysiology and treatment of atopic dermatitis (AD) has shown notable progress. An increasing number of aspects of the immune system are being implicated in AD, including the epithelial barrier, T(H)2 cytokines, and mast cells. Ma …
Recent research into the pathophysiology and treatment of atopic dermatitis (AD) has shown notable progress. An increas …
Biomarkers in atopic dermatitis.
Bakker D, de Bruin-Weller M, Drylewicz J, van Wijk F, Thijs J. Bakker D, et al. J Allergy Clin Immunol. 2023 May;151(5):1163-1168. doi: 10.1016/j.jaci.2023.01.019. Epub 2023 Feb 14. J Allergy Clin Immunol. 2023. PMID: 36792449 Free article. Review.
Atopic dermatitis (AD) is a complex and highly heterogeneous inflammatory skin disease. Given the highly heterogeneous character of AD, it is unlikely that every patient will respond equally to a particular treatment. The recent introduction of novel targeted …
Atopic dermatitis (AD) is a complex and highly heterogeneous inflammatory skin disease. Given the highly heterogeneous charact …
Overview of atopic dermatitis.
Avena-Woods C. Avena-Woods C. Am J Manag Care. 2017 Jun;23(8 Suppl):S115-S123. Am J Manag Care. 2017. PMID: 28978208 Free article. Review.
Atopic dermatitis (AD), also known as atopic eczema, is a chronic relapsing inflammatory skin condition. ...This article reviews the epidemiology, burden of disease, pathophysiology, and diagnostic criteria important for early diagnosis and treatment. …
Atopic dermatitis (AD), also known as atopic eczema, is a chronic relapsing inflammatory skin condition. ...This articl …
Atopic dermatitis: new insight into the etiology, pathogenesis, diagnosis and novel treatment strategies.
Mandlik DS, Mandlik SK. Mandlik DS, et al. Immunopharmacol Immunotoxicol. 2021 Apr;43(2):105-125. doi: 10.1080/08923973.2021.1889583. Epub 2021 Feb 28. Immunopharmacol Immunotoxicol. 2021. PMID: 33645388 Review.
Atopic dermatitis (AD) is the long-lasting chronic inflammatory skin condition associated with cutaneous hyper-reactivity and triggered by environmental factors. ...Therefore, the review highlights the recent advancements in the understanding of clinical features, e …
Atopic dermatitis (AD) is the long-lasting chronic inflammatory skin condition associated with cutaneous hyper-reactivity and …
Treatment With Dupilumab in Patients With Atopic Dermatitis: Systematic Review and Meta-Analysis.
Koskeridis F, Evangelou E, Ntzani EE, Kostikas K, Tsabouri S. Koskeridis F, et al. J Cutan Med Surg. 2022 Nov-Dec;26(6):613-621. doi: 10.1177/12034754221130969. Epub 2022 Oct 9. J Cutan Med Surg. 2022. PMID: 36214355 Review.
Atopic dermatitis (AD) is a type 2 chronic skin disorder associated with systemic and psychosocial comorbidities decreasing the quality of life for many patients. ...Dupilumab decreased the Eczema Area Severity Index (EASI) score [standardized mean difference (SMD) …
Atopic dermatitis (AD) is a type 2 chronic skin disorder associated with systemic and psychosocial comorbidities decreasing th …
Atopic Dermatitis.
Ständer S. Ständer S. N Engl J Med. 2021 Mar 25;384(12):1136-1143. doi: 10.1056/NEJMra2023911. N Engl J Med. 2021. PMID: 33761208 Review. No abstract available.
19,720 results
You have reached the last available page of results. Please see the User Guide for more information.

Searches related to "treatment atopic dermatitis"